The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Gastroesophageal Reflux

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Gastroesophageal Reflux


Psychiatry related information on Gastroesophageal Reflux

  • Uncomplicated GER may be treated by modification of life style and eating habits in an early stage of GERD [6].
  • These studies have led to greater understanding of possible therapeutic applications of mGlu5 receptor antagonists in recent years, suggesting their use in a number of disease states, including chronic pain, various psychiatric and neurological disorders, substance abuse and withdrawal, obesity and gastroesophageal reflux disease (GERD) [7].

High impact information on Gastroesophageal Reflux

  • CONCLUSIONS: mGluR5 antagonists potently inhibit TLESR and reflux in ferrets, implicating mGluR5 in the mechanism of TLESR. mGluR5 antagonists are therefore promising as therapy for patients with GERD [8].
  • Group II (mGluR2 and 3) and group III mGluR (mGluR4, 6, 7, 8) are novel targets for inhibition of vagal signaling with therapeutic potential in, for example, GERD [9].
  • BACKGROUND AND AIMS: Inhibitory G-protein-coupled receptors have demonstrated potential in treatment of gastroesophageal reflux disease (GERD) through actions on vagal afferent signaling [9].
  • CONCLUSIONS: This study provides evidence supporting the independent protective role of cagA-positive H. pylori status and IL1B and ILRN allele polymorphisms against GERD [10].
  • Baclofen effects on esophageal function: a possible therapy for GERD [11]?

Chemical compound and disease context of Gastroesophageal Reflux


Biological context of Gastroesophageal Reflux


Anatomical context of Gastroesophageal Reflux


Gene context of Gastroesophageal Reflux


Analytical, diagnostic and therapeutic context of Gastroesophageal Reflux


  1. Heartburn of pregnancy. Van Thiel, D.H., Gavaler, J.S., Joshi, S.N., Sara, R.K., Stremple, J. Gastroenterology (1977) [Pubmed]
  2. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Lundell, L., Miettinen, P., Myrvold, H.E., Pedersen, S.A., Thor, K., Andersson, A., Hattlebakk, J., Havu, N., Janatuinen, E., Levander, K., Liedman, B., Nyström, P. Gastroenterology (1999) [Pubmed]
  3. Barrett esophagus: will effective treatment prevent the risk of progression to esophageal adenocarcinoma? Sharma, P. Am. J. Med. (2004) [Pubmed]
  4. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Kuipers, E.J., Nelis, G.F., Klinkenberg-Knol, E.C., Snel, P., Goldfain, D., Kolkman, J.J., Festen, H.P., Dent, J., Zeitoun, P., Havu, N., Lamm, M., Walan, A. Gut (2004) [Pubmed]
  5. The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Ofman, J.J., Gralnek, I.M., Udani, J., Fennerty, M.B., Fass, R. Am. J. Med. (1999) [Pubmed]
  6. Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Storr, M., Meining, A., Allescher, H.D. Digestive diseases (Basel, Switzerland) (2000) [Pubmed]
  7. Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications. Slassi, A., Isaac, M., Edwards, L., Minidis, A., Wensbo, D., Mattsson, J., Nilsson, K., Raboisson, P., McLeod, D., Stormann, T.M., Hammerland, L.G., Johnson, E. Current topics in medicinal chemistry. (2005) [Pubmed]
  8. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Frisby, C.L., Mattsson, J.P., Jensen, J.M., Lehmann, A., Dent, J., Blackshaw, L.A. Gastroenterology (2005) [Pubmed]
  9. Metabotropic glutamate receptors inhibit mechanosensitivity in vagal sensory neurons. Page, A.J., Young, R.L., Martin, C.M., Umaerus, M., O'Donnell, T.A., Cooper, N.J., Coldwell, J.R., Hulander, M., Mattsson, J.P., Lehmann, A., Blackshaw, L.A. Gastroenterology (2005) [Pubmed]
  10. IL1B and IL1RN polymorphic genes and Helicobacter pylori cagA strains decrease the risk of reflux esophagitis. Queiroz, D.M., Guerra, J.B., Rocha, G.A., Rocha, A.M., Santos, A., De Oliveira, A.G., Cabral, M.M., Nogueira, A.M., De Oliveira, C.A. Gastroenterology (2004) [Pubmed]
  11. Baclofen effects on esophageal function: a possible therapy for GERD? Hasler, W.L. Gastroenterology (2002) [Pubmed]
  12. Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease. Armstrong, D. Lancet (2000) [Pubmed]
  13. Effect of cimetidine in symptomatic gastro-oesophageal reflux. Powell-Jackson, P., Barkley, H., Northfield, T.C. Lancet (1978) [Pubmed]
  14. Comparative effects of metoclopramide and bethanechol on lower esophageal sphincter pressure in reflux patients. McCallum, R.W., Kline, M.M., Curry, N., Sturdevant, R.A. Gastroenterology (1975) [Pubmed]
  15. Dietary caloric density and osmolality influence gastroesophageal reflux in infants. Sutphen, J.L., Dillard, V.L. Gastroenterology (1989) [Pubmed]
  16. Diagnosis of gastro-oesophageal reflux in infants and children by methylene-blue test. Girardi, G., Fritis, E., Vial, L., Hevia, E. Lancet (1978) [Pubmed]
  17. Effect of cisapride on delayed gastric emptying in gastro-oesophageal reflux disease. Maddern, G.J., Jamieson, G.G., Myers, J.C., Collins, P.J. Gut (1991) [Pubmed]
  18. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Schwab, M., Klotz, U., Hofmann, U., Schaeffeler, E., Leodolter, A., Malfertheiner, P., Treiber, G. Clin. Pharmacol. Ther. (2005) [Pubmed]
  19. Effect of cisapride on secondary peristalsis in patients with gastroesophageal reflux disease. Holloway, R.H., Penagini, R., Schoeman, M.N., Dent, J. Am. J. Gastroenterol. (1999) [Pubmed]
  20. Composition of the postprandial refluxate in patients with gastroesophageal reflux disease. Sifrim, D., Holloway, R., Silny, J., Tack, J., Lerut, A., Janssens, J. Am. J. Gastroenterol. (2001) [Pubmed]
  21. Review article: epidemiology and management of gastro-oesophageal reflux in children. Gold, B.D. Aliment. Pharmacol. Ther. (2004) [Pubmed]
  22. Reflex mechanisms in gastroesophageal reflux disease and asthma. Canning, B.J., Mazzone, S.B. Am. J. Med. (2003) [Pubmed]
  23. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease. Metz, D.C., Pratha, V., Martin, P., Paul, J., Maton, P.N., Lew, E., Pisegna, J.R. Am. J. Gastroenterol. (2000) [Pubmed]
  24. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Bate, C.M., Griffin, S.M., Keeling, P.W., Axon, A.T., Dronfield, M.W., Chapman, R.W., O'Donoghue, D., Calam, J., Crowe, J., Mountfords, R.A., Watts, D.A., Taylor, M.D., Richardson, P.D. Aliment. Pharmacol. Ther. (1996) [Pubmed]
  25. Bradykinin, coronary artery disease and gastro-oesophageal reflux. Caldwell, M.T., Byrne, P.J., Marks, P., Walsh, T.N., Hennessy, T.P. The British journal of surgery. (1994) [Pubmed]
  26. Enhanced expression of interleukin-8 and activation of nuclear factor kappa-B in endoscopy-negative gastroesophageal reflux disease. Isomoto, H., Saenko, V.A., Kanazawa, Y., Nishi, Y., Ohtsuru, A., Inoue, K., Akazawa, Y., Takeshima, F., Omagari, K., Miyazaki, M., Mizuta, Y., Murata, I., Yamashita, S., Kohno, S. Am. J. Gastroenterol. (2004) [Pubmed]
  27. TFF3 expression at the esophagogastric junction is increased in gastro-esophageal reflux disease (GERD). Peitz, U., Kouznetsova, I., Wex, T., Gebert, I., Vieth, M., Roessner, A., Hoffmann, W., Malfertheiner, P. Peptides (2004) [Pubmed]
  28. Gastroesophageal reflux disease is associated with enteric hormone abnormalities. Perdikis, G., Wilson, P., Hinder, R.A., Redmond, E.J., Wetscher, G.J., Saeki, S., Adrian, T.E. Am. J. Surg. (1994) [Pubmed]
  29. Expression of CXC receptor 1 and 2 in esophageal mucosa of patients with reflux esophagitis. Isomoto, H., Kanazawa, Y., Nishi, Y., Wen, C.Y., Inoue, K., Kohno, S. World J. Gastroenterol. (2005) [Pubmed]
  30. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Heudebert, G.R., Marks, R., Wilcox, C.M., Centor, R.M. Gastroenterology (1997) [Pubmed]
  31. Effect of cisapride on postprandial gastro-oesophageal reflux. Holloway, R.H., Downton, J., Mitchell, B., Dent, J. Gut (1989) [Pubmed]
  32. The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms. Blustein, P.K., Beck, P.L., Meddings, J.B., Van Rosendaal, G.M., Bailey, R.J., Lalor, E., Thomson, A.B., Verhoef, M.J., Sutherland, L.R. Am. J. Gastroenterol. (1998) [Pubmed]
  33. Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Schenk, B.E., Festen, H.P., Kuipers, E.J., Klinkenberg-Knol, E.C., Meuwissen, S.G. Aliment. Pharmacol. Ther. (1996) [Pubmed]
WikiGenes - Universities